Brain cancer vax promising in PhI

A small Phase I trial of an experimental dendritic cell-based brain cancer vaccine advanced by ImmunoCellular Therapeutics (IMUC) has produced some unusually positive results. Only 16 patients suffering from glioblastoma multiforme--the most common of all brain cancers--were recruited for the study. But researchers report that 18 months after treatment began, almost half of the patients were still alive without any worsening of their disease. Report